Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalent Inc (NY: CTLT )

61.86 +0.43 (+0.70%)
Streaming Delayed Price Updated: 1:42 PM EST, Dec 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalent Inc

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Catalent Announces Changes to its Board of Directors
From Catalent, Inc.
Via Business Wire
Can Stocks Buck The Rising Odds Of A Recession?
The S&P 500 rose 1.1% and ended the week above its 200-day moving average. Fed Chair Powell spurred a strong rally in stocks on Wednesday, saying interest rates could rise less in December compared to... 
Via Talk Markets
Battered FTX's CEO Sam Bankman-Fried Arrested, Elon Musk's SpaceX Mammoth Valuation Of $140B, China Weighs Over $143B In Semiconductor Push: Top Stories Tuesday, Dec. 13
Benzinga Sam Bankman-Fried Arrested In The Bahamas 
Via Benzinga
Why Shares of Catalent Fell 36% This Week
Lowered guidance and earnings concerned investors. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Thursday
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
7 Analysts Have This to Say About Catalent
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within the last quarter: 
Via Benzinga
After US Launch Bottlenecks, Novo Nordisk Pushes European Rollout For Wegovy In 2023
Novo Nordisk A/S (NYSE: NVO) will roll out its obesity treatment, Wegovy (semaglutide), in Europe in 2023 to ensure it has enough supply. 
Via Benzinga
After a $100 Haircut, is Catalent an Oversold Pharma Play?
With the macro backdrop weakening for Catalent’s pharmaceutical and biotech customers, fundamental concerns could outweigh what the charts suggest. 
Via MarketBeat
Catalent, Inc. to Present at the Stephens Annual Investment Conference
From Catalent, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022
Upgrades 
Via Benzinga
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
From Exelixis, Inc.
Via Business Wire
Where Catalent Stands With Analysts
Over the past 3 months, 11 analysts have published their opinion on Catalent (NYSE:CTLT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Upgrades 
Via Benzinga
Analyst Ratings for Catalent
Over the past 3 months, 8 analysts have published their opinion on Catalent (NYSE:CTLT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Catalent Stock Plummeted by Nearly 25% Today
Flat revenue growth, a sharp decline in profitability, and reduced guidance combined to make an awful day for the company. 
Via The Motley Fool
Nasdaq Down 60 Points; Eli Lilly Lowers Earnings Forecast
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 70 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Unity Biotechnology (UBX) Stock Pops on Positive Study Data
Unity Biotechnology (UBX) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325. 
Via InvestorPlace
Why Is Catalent (CTLT) Stock Down 24% Today?
Catalent (CTLT) stock is falling on Tuesday as investors react to dismal results in its earnings report for the fiscal first quarter of 2023. 
Via InvestorPlace
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
Gainers Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads. 
Via Benzinga
Dow Drops Over 200 Points; Crude Oil Rises Sharply
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Tuesday. 
Via Benzinga
Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
US Stocks Trade Lower Ahead Of Fed Meeting; Pfizer Earnings Top Views
U.S. stocks traded lower this morning, with the Dow Jones dropping around 80 points on Tuesday. 
Via Benzinga
Recap: Catalent Q1 Earnings
Catalent (NYSE:CTLT) reported its Q1 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Catalent missed estimated earnings by... 
Via Benzinga
Catalent, Inc. Reports First Quarter Fiscal 2023 Results
From Catalent, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 96 stocks hit new 52-week lows. 
Via Benzinga
Catalent, Inc. Announces First Quarter Fiscal Year 2023 Earnings Conference Webcast
From Catalent, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  During Friday, 125 stocks hit new 52-week lows. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.